CJC-1295 isn't available on pharmacy shelves in Clécy or anywhere else for that matter — it's a research-grade peptide supplied via a dedicated online market. This matters because CJC-1295 quality varies dramatically across the market — from analytically confirmed high-purity product to material with significant impurity issues — and the vendor is the entire quality system. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide gives Clécy researchers the practical tools to evaluate CJC-1295 vendors systematically and source high-purity CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Clécy comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Quality CJC-1295 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are signalling genuine quality commitment. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger severe inflammatory responses even at very low concentrations. For Clécy researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is standard practice in the community. Keep lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Clécy
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
